Douglas William Bonhaus, PhD, has more than 20 years of experience in the pharmaceutical industry leading drug-discovery efforts targeting neuropsychiatric and neurological disorders. Prior to assuming leadership of drug-discovery at Neuropore Therapies, Dr. Bonhaus led drug discovery groups at Syntex Research, Roche Biosciences and ACADIA Pharmaceuticals. Significant drug-discovery accomplishments include leading teams that discovered a 5-HT2B receptor antagonist for the prevention of migraine; a 5-HT6 receptor antagonist for the treatment of Alzheimer’s disease and; a muscarinic receptor partial agonist for the treatment of schizophrenia. In addition to leading drug discovery efforts, Dr. Bonhaus has successful applied for extramural funding from federal granting agencies, is an inventor on several patents and has co-authored more than 100 publications in peer-reviewed journals.